![]() |
市場調査レポート
商品コード
1439236
心臓ポンプ装置 - 世界市場の考察、競合情勢、市場予測(2030年)Heart Pump Device - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
心臓ポンプ装置 - 世界市場の考察、競合情勢、市場予測(2030年) |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の心臓ポンプ装置の市場規模は、2023年に27億3,000万米ドル、2030年までに63億5,000万米ドルに達し、2024年~2030年の予測期間にCAGRで15.16%の成長が見込まれます。心臓ポンプ装置の需要は、主に心血管疾患(CVD)の有病率の増加、老年人口の増加、パイプライン段階にある製品を持つさまざまな企業によって促進されています。心臓ポンプ装置はCOVID-19の心不全症例で非常に有益であることが判明し、パンデミック状況下でこれらの装置の需要をさらに押し上げました。心臓サプライヤーが不足しているため、心臓ポンプは世界市場の拡大を促す最適なソリューションとなっています。それにもかかわらず、ポンプの高いコストや発展途上国市場における低返済シナリオといった要因が、市場の成長を抑制すると予測されています。
心臓ポンプ装置の市場力学
米国心臓協会(American Heart Association)(2022)によると、2020年に世界で約2億4,410万人が冠動脈(虚血)性心疾患を患っています。
British Heart Foundation(2022)が提供したデータによると、2019年に全世界で約5億5,000万人、つまり14人に1人が心臓および循環器の疾患とともに生活しており、これには約2億9,000万人の女性と約2億6,000万人の男性が含まれます。
上記の資料はさらに、冠動脈(虚血性)心疾患、末梢動脈(血管)疾患、脳卒中、心房細動が2019年に世界でもっとも一般的で有病率の高い心血管疾患であると述べています。
全米保健機関(PAHO)(2022)によると、心血管疾患は他のどの疾患よりも年間死亡者数が多いです。心臓病と脳卒中に関連する死亡は、2021年の低中所得国における死亡全体の4分の3超を占めています。
心臓ポンプ装置に関する研究開発活動の増加は、心臓ポンプ装置市場の成長をさらに後押しします。例えば2022年8月、AbbottはMOMENTUM 3試験から得られたデータに基づき、同社のHeartMate 3心臓ポンプが心不全患者の生存期間を少なくとも5年延長すると発表しました。
したがって、前述の要因が今後数年間、心臓ポンプ装置市場全体を押し上げると見込まれます。
しかし、ポンプの高いコストと発展途上国における低返済シナリオが、心臓ポンプ装置市場の成長抑制要因として作用する可能性があります。
心臓ポンプ装置市場のセグメント分析
心臓ポンプ装置市場の製品セグメントでは、補助人工心臓カテゴリに属する左室補助人工心臓(LVAD)が最大のシェアを占めると予測され、これは市場でもっとも急成長しているセグメントの1つです。
これは主に、LVADに関連する利点と用途に加え、技術の進歩、臓器提供者の不足、世界の心不全の有病率の増加に起因しています。
LVADは正常な血流を回復させることによる重症心不全患者の治療を目的としています。心不全患者へのLVADの移植は救命につながり、臓器移植までの時間を稼ぐことができます。
LVADは信頼性が高く、安全システムが組み込まれています。
LVADの植込み後、患者は健康状態の向上を見せ、運動やその他の日常活動に復帰/再開することができます。
LVADは重症心不全患者に中長期的な治療ソリューションを提供します。
したがって、上記のすべての要因が心臓ポンプ装置市場の成長を促進すると予測されます。
北米が心臓ポンプ装置市場全体を独占する見込みです。
予測期間に北米が心臓ポンプ装置市場全体を独占すると予測されます。これは国内における、心血管疾患(CVD)の巨大な患者人口や、製品開発や市場の発展において非常に強力な市場であること、消費者の高い認知度、地域の主要市場企業のプレゼンスなどによるものと考えられ、これらが市場成長を促進しています。
当レポートでは、世界の心臓ポンプ装置市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
Heart Pump Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of cardiovascular diseases (CVDs) and increasing research and development activities
The global heart pump devices market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030. The demand for heart pump devices is primarily motivated by the increase in cardiovascular disease (CVDs) prevalence, the rise in the geriatric population, and various companies with products in their pipeline phase. Heart Pump devices were found to be extremely beneficial in heart failure cases in COVID-19 which further pushed for the demand for these devices during the pandemic situation. Due to a scarcity of heart suppliers, cardiac pumps are an optimal solution that encourages Global market expansion. Factors such as the high cost of the pump and a low repayment scenario in developing countries are nevertheless projected to inhibit the growth of the market.
Heart Pump Devices Market Dynamics:
According to the American Heart Association 2022, about 244.1 million people were globally living with coronary (ischemic) heart disease in 2020.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
According to Pan American Health Organization (PAHO) 2022, cardiovascular diseases cause more deaths yearly than any other disease. Heart disease and stroke-related fatalities account for more than three-quarters of all deaths in low- and middle-income nations in 2021.
The increasing number of research and development activities pertaining to heart pump devices is further going to assist in the growth of the heart pump devices market. For example, in August 2022, Abbott based upon data obtained from the MOMENTUM 3 trial announced that its HeartMate 3 heart pump extends the survival of heart failure patients by at least five years.
Therefore, the afore-said factor will propel the overall market of heart pump devices in the upcoming years.
However, the high cost of the pump and low repayment scenario in developing countries may act as a restraint in the growth of the heart pump devices market.
Heart Pump Devices Market Segment Analysis:
Heart Pump Devices by Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the heart pump devices market, left ventricular assist devices (LVAD) under the ventricular assist devices category are expected to hold the largest share and are one of the fastest-growing segments in this market.
It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.
LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.
LVADs are highly reliable and come with built-in safety systems.
Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.
LVADs offer intermediate to long-term treatment solutions for severe heart failure patients.
Hence, all the above-mentioned factors are expected to drive the segment growth of the heart pump devices market.
North America is expected to dominate the overall Heart Pump Devices Market:
North America is expected to dominate the overall Heart Pump Devices market during the forecast period. This can be ascribed to the presence of a large patient pool suffering from cardiovascular diseases (CVDs), the highly potent market in terms of product development and launches, high consumer awareness, and the presence of local key market players among other factors in the country, driving the market growth.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.
Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
The increasing number of product development activities in the region is further going to accelerate the growth of the heart pump devices market. For example, in August 2021, the US Food and Drug Administration granted a breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
Thus, due to the increase in demand for heart pump devices in the region, there will be a subsequent rise in the growth of heart pump devices regional market during the forecast period.
Heart Pump Devices Market Companies:
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
Recent Developmental Activities in the Heart Pump Devices Market:
In August 2021, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous Heart Pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
In February 2021, CARMAT received FDA approval to conduct an Early Feasibility Study (EFS) of its Total Artificial Heart in the US using BlueSync technology.
In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.
Key Takeaways from the Heart Pump Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Heart Pump Devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the Global Heart Pump Devices Market.
Various opportunities are available for the other competitor in the Heart Pump Devices Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Heart Pump Devices market growth in the coming future?
Target Audience who can be benefited from This Heart Pump Devices Market Report Study
Heart Pump Devices providers
Research organizations and consulting companies
Heart Pump Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Heart Pump Devices
Various End-users want to know more about the Heart Pump Devices Market and the latest technological developments in the Heart Pump Devices market.
Frequently Asked Questions for the Heart Pump Devices Market:
What are Heart Pump Devices?
Heart pump devices are utilized in patients that are suffering from heart issues such as a recent cardiac arrest. They carry out the normal functions of the heart by maintaining regular cardiac circulation and replacing the heart partially or completely. After receiving the blood from the heart's lower chambers, it helps transfer the blood to all the vital organs in the body.
What is the market for Global Heart Pump Devices?
Global Heart Pump Devices Market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030.
What are the drivers for Global Heart Pump Devices?
The major drivers driving the demand for Heart Pump Devices are the increasing prevalence of cardiovascular diseases, the rising geriatric population, and new product development by the market players.
What are the key players operating in Global Heart Pump Devices?
Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.
What regions have the highest share in the Heart Pump Devices market?
North America is expected to dominate the overall Heart Pump Devices market during the forecast period, 2024 to 2030. This domination is due to the growing demand for advanced technologies in Heart Pump Devices, the increasing chronic disease in the region is driving the regional growth.